News and Events
March 31, 2021 – NEWS
Indivumed Launches Spinoff Ix Therapeutics
We are proud to share our recent Precision Oncology News feature story and interview with our CEO Prof. Dr. Hartmut Juhl about the launch of Ix Therapeutics - Indivumed's expansion into target discovery and early cancer drug development for new possibilities in cancer treatment.
Read MoreMarch 18, 2021 – PRESS
Indivumed Announces Expansion Into Drug Development, Formation of Ix Therapeutics
Indivumed GmbH announced today the founding of Ix Therapeutics GmbH, a joint venture with Xlife Sciences AG, which marks Indivumed’s expansion into target discovery and early cancer drug development. The collaboration opens up completely new possibilities for cancer treatment.
Read MoreJanuary 26, 2021 – NEWS
Indivumed appoints Roald Forsberg as new Chief Business Officer
Indivumed appoints Dr. Roald Forsberg as Chief Business Officer and Head of the IndivuType Business Unit. He succeeds Fernando Andreu, who led the IndivuType Business Unit during its early phase.
Read MoreJanuary 05, 2021 – NEWS
A retrospective and outlook
It has been a very special year – with unexpected challenges and global uncertainty putting much of the world at a standstill. With this in mind, we are grateful and proud to look back and see that Indivumed did not stand still – in the face of these challenges, we kept moving forward.
Read MoreResearch Publications
Product Information
Biospecimen Products
To meet all your needs in cancer research and drug development we offer you a broad spectrum of high-quality biospecimen samples including clinical data.
Applications and CRO Services
To further support your efforts in personalized oncology we offer you an holistic range of clinical, laboratory, and research services.
ISO-Certified Expertise
Indivumed GmbH’s long-standing expertise with its business units IndivuServ and IndivuType is ISO 9001:2015-certified and includes the collection of biological samples and clinical data (Biobank), research service in the form of immunohistochemistry, analysis of signaling proteins, drug testing, establishment of primary cell cultures and molecular biology, bioinformatic and biomedical data analysis.
Download the ISO-Certificate
Media
Discover more about Indivumed’s work and the future of personalized cancer medicine in the following lectures and videos.
Image
Partners
Global Clinical Network:
Prof. Jesus Garcia Foncillas - Hospital Universitario Fundacion Jimenez Diaz
Global Clinical Network:
Dr. Rafael López López - Hospital Clínico Universitario de Santiago
Global Clinical Network:
Dr. Xavier Matias-Guiu - Hospital Universitario Arnau de Vilanova Lleida
Global Clinical Network:
Prof. Gerry Melino - Hospital Tor Vergata Italy
Global Clinical Network:
Prof. Sun Young Rha - Severance Hospital Yonsei University Health System
Global Clinical Network:
Dr. Carlos Sampaio - Clinica AMO Brazil
Global Clinical Network:
Prof. Takayuki Yoshino – National Cancer Center Hospital East Japan
Cooperational Partnership:
Gnosis Data Analysis
Cooperational Partnership:
Biognosys AG
Scientific Lectures
22CEMIT Symposium: Overview and Perspectives for Translating Multi-omics into Clinical Utility in Solid Tumors. Speaker: Prof. Dr. Hartmut Juhl
Next In Personalized Medicine - Cancer-Phenotyping
Speaker: Hartmut K. Land, Ph.D., Prof. Dr. Hartmut Juhl
Personalized Oncology – Why Tissue Is the Issue When Characterizing Tumor Expression
Speaker: Dr. Bernd Gromoll, Prof. Dr. Hartmut Juhl
Opening Remarks and The Importance of Biobanking on Personalized Medicine
Speaker: Carolyn Compton
The Challlenge and Importance of Standardizing Pre-Analytical Variables in Surgical Pathology Specimens for Clinical Care and Translational Research. Speaker: David Hicks
How to Assess Tissue Quality to Improve Tissue Diagnostics
Speaker: Jim Crawford
The Future of Personalized Medicine in Oncology Has Begun
Speaker: John Marshall
IndivuType: Indivumed's Global Cancer Database Solution for Drug Development and Patient Care. Speaker: Hartmut Juhl